Lakewood-Amedex Biotherapeutics Inc.(LABT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LABT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Lakewood-Amedex Biotherapeutics Inc. (LABT), a Healthcare sector company. LABT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Lakewood-Amedex Biotherapeutics Inc. reports net income of $-923.3K, free cash flow of $-349.7K. LABT trades on the Nasdaq exchange and files with the SEC under CIK 2079272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lakewood-Amedex Biotherapeutics Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-923.3K
Free Cash Flow
Q1 2026
$-349.7K
Get alerted when LABT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Lakewood-Amedex Biotherapeutics Inc. including:
More Healthcare Companies
View all Healthcare →Put LABT on your watchlist
Track score changes the day Lakewood-Amedex Biotherapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LABT a good stock to buy?
13F Pro's AI-powered analysis of Lakewood-Amedex Biotherapeutics Inc. (LABT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LABT are available on the LABT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LABT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LABT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lakewood-Amedex Biotherapeutics Inc.'s investment landscape.